Fulvestrant

Overview

Fulvestrant is an estrogen receptor antagonist used in the treatment of hormone receptor-positive metastatic breast cancer. It binds to estrogen receptors and promotes their degradation, thereby inhibiting their biological activity.

API suppliers (5)

Suppliers of Fulvestrant backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• HANGZHOU JIUYUAN GENE ENGINEERING CO LTD1 active DMF
• SCINOPHARM TAIWAN LTD1 active DMF
• SCINOPHARM TAIWAN LTD1 active DMF
• CHEMWERTH INC
• Taro Pharmaceutical Industries Ltd.Israel

Patent & exclusivity (US)

Per the FDA Orange Book (14 approved US products), the latest listed US patent on Fulvestrant expires 16 May 2034. Generic API sourcing typically opens up once these lapse.

Therapeutic areas